Loading company
Mannkind Corp.
MNKD · Nasdaq · ·
Next earnings: November 4, 2026
$3.34-0.9%Sep 29 close
- 1M
- -15.4%
- 6M
- +40.9%
- 1Y
- -37.8%
- 5Y
- -30.4%
MNKD · Nasdaq · ·
Next earnings: November 4, 2026
$3.34-0.9%Sep 29 close
Mannkind Corp. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $109.4M | $76.5M | +42.92% |
| Profit | -$19M | $668K | -2,949.10% |
| Profit per share | -$0.06 | $0.00 | — |
| Free Cash Flow | -$23.5M | $7.8M | -399.41% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“This was a transformative period for MannKind, during which we delivered all three major catalysts we set out to achieve in 2026,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life. Learn more at mannkindcorp.com.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Mannkind Corp.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Mannkind Corp. has no earnings call transcript available.